Vor Biopharma Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 117.86 million compared to USD 92.09 million a year ago. Basic loss per share from continuing operations was USD 1.75 compared to USD 2.33 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.145 USD | -0.43% | -4.58% | -49.11% |
13/06 | Voyager Therapeutics Names Nathan Jorgensen as Finance Chief | MT |
10/06 | Vor Biopharma Inc. Announces Management Appointments, Effective June 21, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.11% | 78.5M | |
+20.84% | 46.93B | |
+37.63% | 39.08B | |
-8.13% | 38.48B | |
+29.10% | 31.01B | |
-13.75% | 26.14B | |
+11.09% | 25.88B | |
+37.01% | 12.53B | |
-7.09% | 11.36B | |
-12.62% | 10.65B |
- Stock Market
- Equities
- VOR Stock
- News Vor Biopharma Inc.
- Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023